209959-25-1

Basic information

• Product Name: tert-butyl 4-(4-nitrophenyl)-1H-pyrazole-1-carboxylate
• Synonyms: tert-butyl 4-(4-nitrophenyl)-1H-pyrazole-1-carboxylate
• CAS NO: 209959-25-1
• Molecular Weight: 289.291
• Mol File: 209959-25-1.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-nitrophenyl)-1H-pyrazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-nitrophenyl)-1H-pyrazole-1-carboxylate(209959-25-1)
• EPA Substance Registry System: tert-butyl 4-(4-nitrophenyl)-1H-pyrazole-1-carboxylate(209959-25-1)

Safety Data

• Hazardous Substances Data: 209959-25-1(Hazardous Substances Data)

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 552846-17-0 tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate 
• 586-78-7 para-nitrophenyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 114474-26-9 4-(4-nitrophenyl)-1H-pyrazole 
• 209959-24-0 C₁₁H₂₀N₂O₂Sn 

Downstream Products

• 209959-26-2 tert-butyl 4-(4-aminophenyl)-1H-pyrazole-1-carboxylate 
• 1610874-68-4 N-(4-(1H-pyrazol-4-yl)phenyl)-3-(2-chlorophenyl)propanamide 
• 1610875-33-6 tert-butyl 4-(4-(3-(2-chlorophenyl)propanamido)phenyl)-1H-pyrazole-1-carboxylate 

Relevant articles and documents

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

CYCLIN-DEPENDENT KINASE INHIBITORS

Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).